CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases 2017

Biocon  /  News – Posts  /  Press Releases  /  Press Releases 2017

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs

  • Posted by: BIOCON

U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers

  • Posted by: BIOCON

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim

  • Posted by: BIOCON

Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India

  • Posted by: BIOCON

Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore

  • Posted by: BIOCON

Biocon Ranked Among Top 10 Global Pharma & Biotech Employers

  • Posted by: BIOCON

JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment

  • Posted by: BIOCON

Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore

  • Posted by: BIOCON

FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab

  • Posted by: BIOCON

Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s 77th Scientific Sessions

  • Posted by: BIOCON
  • 1
  • 2
Share
Previous Next
Close
Test Caption
Test Description goes like this